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This book gives an overview of a frequently neglected area of
cancer that at best has had patchy coverage in the past, namely the
relationship between the biochemical changes that occur in cancer
patients resulting from an increasing and progressive tumour
burden, increased secretion of inappropriate substances and the
effects of cytotoxic therapy on biochemical homeostasis.
The book is divided into six chapters: The Nature of
Malignancy, The Biochemical Effects of Tumour Growth, Tumours
and Tumour Markers – General Considerations, Tumours and
Tumour Markers – Applications, Paraneoplastic Syndromes and
The Treatment of Cancer.
The presentation in this book is of a high standard, with very
clear figures and tables, and the information is given in a logical
order. Many of the aspects discussed are illustrated with inter-
esting case histories that reinforce the information in the text. At
the end of each chapter are up-to-date references that look useful
and allow the reader to expand their knowledge base in the partic-
ular area that interests them. Although the style of writing is
didactic, the authors give balanced arguments for their views or
reasons for the statements they make, and you often feel that they
are speaking from personal experience. Their message is clear and
precise. The book also has a good index and there are very few
typographical errors.
The book starts with an introduction to cancer which, although
superficial, presents an up-to-date view of the field, bringing in
factors such as proto-oncogenes/suppressor genes, DNA repair
and inherited cancers. Also, at the end of the chapter the authors
discuss the possibility of molecular biology tools being used to
investigate cancer in the future. This chapter will be valuable for
anyone who is a bit unsure about the nature of cancer or who is a
bit rusty on recent developments in the field and would like to be
brought up to speed.
In considering the biochemical effects of the tumour on the host
(Chapter 2), the authors discuss both the effects of metastasis on
specific organs, for example liver or bone involvement, as well as
more generalized damage caused by a growing and increasing
primary tumour mass. The release of tumour products and the host
tissue response to injury are also considered. The examples and
illustrations for this part are excellent.
Chapter 2 leads naturally into the first of the two chapters on
tumour markers. The first provides a realistic overview of a field
which, in the past, has generated numerous molecules that have
claimed to be useful for monitoring cancer. Sensibly, the authors
mainly restrict their comments to well-established markers such as
CEA, alpha-fetoprotein, HCG and the so called ‘cancer antigens’
on mucins. Another focus of this chapter is a section on the inter-
pretation of tumour markers, their limitations and the problems
with assay variability. Standard topics such as sensitivity, speci-
ficity and receiver operating characteristic curves are also covered.
Chapter 4 is concerned with applications of specific tumour
markers. This is approached by describing markers used to investi-
gate tumours that arise in various body sites, for example gastro-
intestinal tract, breast, lung, ovary. This chapter is the longest in
the book and is packed with information, giving ranges, speci-
ficity, sensitivity and recommendations for use on a wide range of
cancer markers. Again, information is well organized and clearly
presented with a number of interesting case histories.
The last two chapters of this book are directed more at the dedi-
cated reader of the book rather than the casual browser. Chapter 5
is concerned with the paraneoplastic syndromes and would require
a reasonable amount of previous knowledge in clinical biochem-
istry to obtain the maximum benefit from it. Many situations in
which tumours produce inappropriate hormones are documented
in detail. In chapter 6, the authors give an excellent summary of
the cytotoxic chemotherapies that are available for cancer treat-
ment and their mechanism of action. This leads to a final section
that describes drug toxicity and how diagnostic biochemistry can
help in monitoring these effects.
This book is not very long, 136 pages, but every page is packed
with valuable information. Although it is aimed primarily at the
professional clinical biochemist, its scope and clarity will appeal
to a wide range of readers from the undergraduate student who is
studying medicine or a medically related science through to the
hospital oncologist.
GA Turner,
Department of Clinical Biochemistry Medical School,
Framlington Place,
Newcastle-upon-Tyne  NE2 4HH
Improving Care for Patients with Malignant
Cerebral Glioma
Edited by E Davies and A Hopkins, pp 123
This is an excellent book which represents an outstanding
summary of the current perspectives for the management of
patients with glioma. It contains 12 chapters in 123 pages, and
each of the chapters is appropriately referenced. An appendix is
also included containing audit proformas for various issues of
patient care for this condition. The book is a publication from a
Royal College of Physicians Working Party on Malignant Cerebral
Glioma and accompanies an article published by the same group in
1997 in Br J Neurosurg 11, 318–330. In many ways, the book
represents a more straightforward summary and contains addi-
tional information on the psychological aspects of care in this
depressing condition.
There are important technical sections in the book. These
include the issue of confirming the diagnosis and specific chapters
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The issue of steroids is also discussed. There are resolved issues in
the surgical treatment of glioma and regarding some of the aspects
of radiotherapy. The issues are well described, and appropriate and
helpful conclusions are drawn.
In the chapters dealing with the psychological aspects of the
condition, there are chapters on breaking bad news, and one of
these is written by the relative of a patient. This is written with
considerable insight and has some extremely constructive points
to make. From my personal point of view, I was disappointed
that this chapter had relatively little to say about the period
between surgical diagnosis and the commencement of radio-
therapy treatment.
There are three chapters dealing with follow-up services and
their organization, including one excellent chapter describing an
alternative method of follow-up using a neuro-oncology nurse
specialist and a ‘telephone clinic’. It is noteworthy that this book
supports the concept of follow-up at a time when this has been crit-
icized from the perspective of a number of other tumour types in
oncology.
The book also contains an interesting chapter on what general
practitioners want to know about the condition, although, in my
own experience, there is a considerable spectrum in the sort of
information about the condition which individual GPs want or
need to receive. There is a valuable chapter on palliative care,
particularly in the community setting. The final chapter of the
book is written from the perspective of a purchaser. This repre-
sents an interesting angle, and is very much more in line with the
objectives of medical nursing and supportive care than one might
otherwise have thought.
The final section of the book contains audit proformas for eval-
uating management, both of individual patients and treatment
centres. There are several proformas looking at all aspects of
patient care, including information giving, breaking bad news,
technical aspects, follow-up details and management at time of
relapse. These proformas have obviously been collated carefully.
The reader is invited to photocopy these, because they are free
from copyright, if they are considered helpful. Overall, I find
this the weakest part of the book, purely because many of the
proforma questions seem a little too superficial to reflect the very
complex nature of this illness. Nevertheless, it is a valiant attempt
to document what is or is not being achieved and can be used to
assess the benefit of new strategies. It may well be that such infor-
mation will help individual centres to develop their neuro-
oncology service.
This book represents an outstanding summary of all aspects of
the current clinical management of patients with malignant cere-
bral glioma. It is to be commended to anyone working in this field,
including medical and surgical trainees, nurses, managers and
purchasers. I hope the book will be revised from time to time,
particularly in response to publication of important new informa-
tion. Meanwhile, the book is extremely cheap considering its
content, and should be on the bookshelf of all of us involved in the
care of patients with malignant cerebral glioma.
Neil Burnett
University of Cambridge
Box 193
Addenbrooke's Hospital
Cambridge CB2 2QQ
Apoptosis and Cancer
Edited by J Martin, Karger Landes Systems, pp 265
The process by which cancer cells may undergo a programmed
cell death or apoptosis represents a 1990s burgeoning area of
cancer research following on from the original seminal studies of
Kerr and Wyllie in the early 1970s. This is reflected in the 
exponential increase in papers on apoptosis during the 1990s,
numerous sessions at international cancer conferences and various
books being devoted to the subject. This book, comprising 13
chapters from an international array of authors and 265 pages and
published by Karger Landes Systems, is ambitious in attempting 
to compile, in a coherent manner, the latest developments. A little
disappointing from a publishing viewpoint is the rather mono-
chrome appearance of the book cover: a computer graphic of an
apoptosing cancer cell or death pathway may have more 
immediate appeal to the casual bookshelf browser!
The early chapters (‘Apoptosis and Cancer: an Overview’ and
‘Apoptosis: an Introduction’ by SJ Martin, Maynooth, Ireland) serve
as an appetizer to the later main courses and provide a sound intro-
duction to the field and later, more specialized, contributions.
Chapter 3, ‘Apoptosis and Necrosis in Tumors’, by N Toft and M
Arends from the Wyllie Group in Edinburgh, attempts to clarify the
roles of apoptosis versus necrosis in determining tumour growth
(cell gain versus cell loss) and after chemotherapy. The role of
angiogenesis and the potential of anti-angiogenesis therapy is
mentioned. A minor quibble of Chapter 4 ‘Apoptosis and the Cell
Cycle’, by R Fotedar, L Diederich and A Fotedar (France), is the
lack of a summarizing graphic of the cell cycle and where the
various negative and positive regulators operate. Chapter 5, ‘Bcl-2
Family Proteins: Role in Dysregulation of Apoptosis and
Chemoresistance in Cancer’, by J Reed (La Jolla), is comprehensive
and excellent, and, for me, the highlight of the book. This chapter
covers structural/sequence and, where known, functional details of
the various positive and negative regulators of apoptosis within the
bcl-2 family, their interactions, their role as determinants of
chemoresponsiveness and chemoresistance and their prognostic
significance in various cancer types. The chapter finishes with
details of post-translational modifications of Bcl-2 (e.g. phosphory-
lation by paclitaxel) and possible strategies for inhibiting Bcl-2
function in cancers. Chapter 6 ‘Abl Tyrosine Kinase and the Control
of Apoptosis’ by G Amarante-Mendes and D Green (San Diego)
describes the various members of the Abl family, how oncogenic
forms such as Bcr-Abl confer resistance to apoptosis induction and
the recent important observations connecting c-Abl to stress path-
ways (JNK/SAPK) after DNA damage. The role of p53 in apoptosis
and cancer is covered in Chapter 7, by C Bellamy, R Malcomson
and A Wyllie (Edinburgh). Although there are no illustrations, the
chapter is comprehensive, including the role of p53 in apoptosis,
growth arrest and DNA repair, p53 abnormalities in cancer and a
little on the potential for p53 gene therapy. Following on from p53 is
a consideration of the role of the retinoblastoma gene in the control
of apoptosis (Chapter 8 by K Macleod and T Jacks, Cambridge,
MA, USA). In particular, apoptosis via deregulation of the Rb-
regulated transcription factor, E2F after loss of Rb is described.
Chapters 9–12 focus on apoptosis in a disease or organ setting:
Programmed (apoptotic) Cell Death and Prostate Cancer (S
Denmeade and J Isaacs, Johns Hopkins, Baltimore, USA)
including apoptosis induced by androgen ablation therapy, a short
chapter on Cell Death Regulation in the Kidney and in Renal
186 Book Reviews
British Journal of Cancer (1999) 79(1), 185–187 © Cancer Research Campaign 1999Neoplasms (T McDonnell, S Hewitt and G Saunders, MD
Anderson, Houston, USA), Apoptosis in Leukemia (S McKenna
and T Cotter, Cork, Ireland) and Cell Death in Neuroblastoma
Tumors (G Melino et al, Rome, Italy). The final chapter (13)
‘TNF-based Strategies for Manipulating Apoptosis: Adjuncts to
Cancer Therapy’ (G Wong, G Vehar and R Kaspar, San Francisco
and UT, USA) provides an interesting insight into the possibility of
protecting normal cells while sensitizing tumours using tumour
necrosis factor (TNF) or lymphotoxin (LT) pretreatment.
Although many of the key players in this field have contributed
chapters (e.g. A Wyllie, D Green, J Reed), it is perhaps surprising
that there is no contribution from the Korsmeyer, Hickman/Dive or
Evan groups. The strengths of the book lie in defining the key
players and pathways, regulation and molecular pathology of apop-
tosis. A weakness is in the area of therapeutic exploitation of these
findings. There is a general lack of coverage of new cancer drug
development initiatives within the apoptosis arena (although admit-
tedly much of this is closely guarded within the pharmaceutical
industry and not yet within the public domain). However, for
example, there is little mention of the ongoing bcl2 antisense trials
in follicular lymphoma.
Overall, because of the rapidity of change in this cutting-edge
field, some sections are inevitably already a little out of date; for
example, discussions of the ced4 human homologue Apaf-1 and
the very recent p16INK4/p19ARF products providing dual inactivation
of the Rb and p53 pathways. Nevertheless, the book provides an
excellent entry into the field for undergraduates, postgraduates or
other cancer researchers for whom apoptosis in not their main area
of interest. For the experts, the book is clearly no substitute for
continuing to dip regularly into Nature, Cell, Science, etc.
LR Kelland
Institute of Cancer Research
Clifton Avenue
Sutton
Surrey SM2 5PX
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